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The World Health Organization (WHO) has set elimination as a public health problem (EPHP) as a goal for schistosomiasis. As 
the WHO treatment guidelines for schistosomiasis are currently under revision, we investigate whether school-based or community-
wide treatment strategies are required for achieving the EPHP goal. In low- to moderate-transmission settings with good school 
enrolment, we find that school-based treatment is sufficient for achieving EPHP. However, community-wide treatment is projected 
to be necessary in certain high-transmission settings as well as settings with low school enrolment. Hence, the optimal treatment 
strategy depends on setting-specific factors such as the species present, prevalence prior to treatment, and the age profile of infection.
Keywords. schistosomiasis; mass drug administration; school-based treatment; community-wide treatment; elimination as a 
public health problem.
Schistosomiasis remains an endemic parasitic disease af-
fecting approximately 220 million people around the world 
[1]. Following establishment of the neglected tropical disease 
(NTD) roadmap set by the World Health Organization (WHO), 
elimination as a public health problem (EPHP) was set as the 
2025 goal for schistosomiasis, defined as reaching less than 
1% prevalence of heavy-intensity infections in school-aged 
children (SAC; 5–14 years old) [2, 3]. For intestinal schistoso-
miasis caused by Schistosoma mansoni, heavy-intensity infec-
tions are defined as greater than 400 eggs per gram of feces and 
for urogenital schistosomiasis caused by S. haematobium, this is 
defined as over 50 eggs per 10 mL of urine [4]. Interruption of 
transmission (reducing the incidence of new infections to zero) 
is the end goal set by WHO for countries able to aim for this 
objective [2].
To achieve EPHP, the WHO has recommended treatment 
guidelines based on the prevalence in SAC prior to treatment 
[4, 5]. Current guidelines have focused on targeting SAC as 
they are most likely to be infected, but treatment of adults (≥ 
15  years old) considered to be at risk has also been recom-
mended in areas with higher prevalence [6]. This is important 
given morbidities in adults, such as female genital schistoso-
miasis and the link to HIV. Pediatric treatments are under de-
velopment, which may enable the inclusion of pre-SAC within 
treatment programs [7, 8].
There is a limited supply and availability, particularly in 
Africa, of the treatment drug, praziquantel, used to treat in-
fected individuals. Merck KGaA is currently the sole donor of 
praziquantel with 250 million tablets available annually, prima-
rily for SAC [9]. Praziquantel is typically used in school-based 
(targeting SAC only) or community-wide (targeting both SAC 
and adults) mass drug administration (MDA) programs in 
which a proportion of the population is treated without diag-
nosis of infection. Given the limited supply of praziquantel, it 
is vital that the appropriate treatment strategy is used to pre-
vent unnecessary treatment and to enable the efficient use of 
this valuable resource, allowing redeployment to those needing 
treatment. Additional praziquantel over that available in dona-
tions can be purchased but comes at a further cost for treatment 
programs.
The new NTD roadmap for 2021–2030 is currently under 
discussion, along with the WHO 2030 goals and treatment 
guidelines for schistosomiasis [10]. Through analysis of mathe-
matical models on schistosomiasis transmission dynamics and 
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control measures, we aim to provide guidance on the optimal 
treatment strategies required for achieving EPHP. Importantly, 
we highlight that the decision between adopting a school-
based or community-wide treatment strategy to reach EPHP 
depends on the epidemiological setting, particularly the spe-
cies present, prevalence prior to treatment, and age profile of 
infection.
METHODS
Mathematical models of schistosome transmission and con-
trol have shown that the treatment strategy required to achieve 
EPHP will depend on the prevalence (transmission intensity) 
and age-intensity profile of infection. The age profile of infec-
tion varies as adults can harbor a low to high burden of infec-
tion corresponding to their exposure to infection relative to 
SAC (transmission intensity by age group; see Figure 1A and 
Supplementary Table 1).
Using the Imperial College London model (as previously de-
scribed [11]), we investigated S. mansoni age profiles with low 
to high adult burden settings, and S. haematobium with a low 
burden in the adult population (as tends to be observed for 
S. haematobium; Figure 1A and Supplementary Data). For each 
age profile, we simulated low to high baseline prevalence set-
tings and treated 75% of SAC only annually, for up to 7 years. 
In simulations where this strategy did not achieve EPHP, we 
increased SAC coverage and/or included adult treatment as 
needed. We assumed no migration (model simulations are for 
a single community of 500 individuals) and we assumed no ac-
quired immunity.
RESULTS
In low to moderate baseline prevalence settings (SAC preva-
lence <50% prior to treatment) for S.  mansoni, analyses sug-
gest that EPHP can be achieved by treating 75% SAC only 
annually for up to 3 years. In moderate-prevalence settings for 
S. haematobium, analyses suggest that EPHP can be achieved 
by treating 75% SAC only in 1 round of treatment. Note that 
in some low- to moderate-prevalence settings, the prevalence 
of heavy-intensity infections in SAC may already be under 1%, 
such that the EPHP goal is met prior to any treatment being car-
ried out (Table 1). Despite achieving EPHP, a risk of resurgence 
remains if control efforts are not maintained.
In high baseline prevalence settings (SAC prevalence ≥50% 
prior to treatment), once the prevalence rises above a certain 
point, treatment of both SAC and adults becomes necessary 
[12, 13]. Importantly, adult treatment is not needed in all high-
prevalence settings for achieving EPHP. The specific SAC prev-
alence threshold at which adult treatment is needed to reach 
EPHP varies with the age profile of infection. For S. mansoni, 
analyses suggest that treating 75% SAC only annually for up to 
7 years is sufficient for achieving EPHP if the baseline SAC prev-
alence is below 73% or 59% for a low or high adult burden set-
ting, respectively. For S. haematobium, similar to the low adult 
burden setting for S. mansoni, this holds for baseline SAC prev-
alence below 70%. For baseline SAC prevalence settings above 
these, intensified treatment is needed, such as higher coverage 
of SAC and/or an expansion in treatment coverage to include 
adults (Table 1 and Figure 1B; coverage levels required have 
been shown to increase with the adult burden of infection [12]).
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Figure 1. A, Age-intensity profiles of infection for Schistosoma mansoni using model-simulated low and high adult burdens of infection (relative to school-aged children 
[SAC; 5–14 years old]) and S. haematobium using previous fit to data [15]. B, Schematic showing treatment strategies required for achieving elimination as a public health 
problem (EPHP). Low adult burden of infection settings based on modeling insights on S. mansoni with a low adult burden setting and on S. haematobium. High adult burden 
of infection settings based on modeling insights on S. mansoni with a high adult burden setting. Blue region, 75% SAC-only annual treatment for up to 7 years is sufficient for 
achieving EPHP; green region, increase in school-based treatment coverage (ie, over 75% SAC annual treatment for 7 years) and/or expansion to community-wide treatment 
is needed for achieving EPHP (dashed line, approximate prevalence threshold above which this occurs for given age profiles).
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To achieve EPHP, these modeling insights show that 
school-based treatment (of 75% SAC only) is sufficient in 
low- to moderate-prevalence settings for both S. mansoni and 
S. haematobium (Table 1). In certain high-prevalence settings, 
75% SAC-only treatment remains sufficient for achieving EPHP; 
however, once the prevalence rises above a certain threshold, an 
increase in SAC treatment coverage and/or expansion to adult 
treatment is needed. This prevalence threshold decreases as the 
burden of infection in adults relative to SAC rises (Figure 1B). 
Overall, the optimal treatment strategy will depend on the set-
ting, including factors such as the species present, prevalence 
prior to treatment, age profile of infection, and school enrol-
ment levels.
Note that these insights derived from the predictions of 
mathematical models should not be overgeneralized to all set-
tings. In addition to treatment coverage, individual adherence 
to treatment is also important. Our model assumes that 75% of 
SAC are treated at random in each round of MDA, hence SAC 
not adhering to treatment and SAC with no access to treatment 
(eg, schools with low enrolment) have not been considered. 
In settings with such challenges present, community-wide 
treatment may be more beneficial [14]. Additionally, the 
S.  haematobium age profile of infection studied (informed by 
previous model fitting to data work [15]) has a low adult burden 
of infection but in areas with higher adult levels of infection, 
adult treatment will likely be needed.
Caveats to These Analyses: The Skewed Distribution of Worms in Different 
Communities
Understanding the nonlinear relationship between prevalence 
of infection and heavy-intensity infections is key, particularly if 
the EPHP goal is changed to a goal that is based on prevalence 
of infection (Figure 2). This relationship varies with the degree 
of worm aggregation within a defined community (where a 
high worm aggregation corresponds to most individuals har-
boring zero or few worms and a few individuals harboring 
many) [11]. We know that the uneven distribution of worms 
across a community is common, but there are few measures of 
how variable it is in different places, and how it changes after 
treatment and during resurgence. Following multiple rounds of 
MDA, the degree of worm aggregation may increase, particu-
larly if there are a few systematic nonadherers and/or nonaccess 
individuals remaining with heavy-intensity infections. Such in-
dividuals will reduce the potential impact of a treatment pro-
gram and result in persisting infections, thereby increasing the 
risk of resurgence.
Low prevalence of heavy-intensity infections does not always 
correspond to low prevalence of infection (Figure 2). As a large 
reduction in intensity may be associated with a small reduction 
in prevalence, it is important that both prevalence and inten-
sity data are collected to monitor the impact of a treatment pro-
gram [11, 12, 14]. Even when the EPHP goal is achieved for 
S. mansoni and S. haematobium following treatment (ie, preva-
lence of heavy-intensity infections in SAC reduced to less than 
Table 1. Model Recommended Treatment Strategies Required to Achieve 
EPHP in Low- to High-Prevalence Settings for Schistosoma mansoni and 
S. haematobium 
Prevalence in SAC Prior 
to Treatment Model Recommended Treatment Strategy 
Low (<10%) S. mansoni: 75% SAC annual treatment for 0–1 y 
(no treatment needed where EPHP met prior 
to treatment).
Moderate (10%–50%) S. mansoni: 75% SAC annual treatment for 1–3 y 
(1–2 y for low adult burden of infection and 3 y 
for high adult burden of infection). 
S. haematobium: 75% SAC annual treatment for 
0–1 y (no treatment needed where EPHP met 
prior to treatment).
High (≥50%) S. mansoni and S. haematobium (where base-
line SAC prevalence is 50%–51%): 75% 
SAC annual treatment for up to 1–4 y (1 y for 
S. haematobium; 2 y for low adult burden of 
infection, and 4 y for high adult burden of infec-
tion for S. mansoni).
S. mansoni (where baseline SAC prevalence 
is below 73% and 59%, for low and high 
adult burdens of infection, respectively) and 
S. haematobium (where baseline SAC preva-
lence is below 70%): 75% SAC annual treat-
ment for 7 y.
S. mansoni and S. haematobium (with baseline 
SAC prevalences higher than those above): 
Increase in school-based treatment coverage 
(ie, over 75% SAC annual treatment for 7 y) 
and/or expansion to community-wide treatment 
needed. Coverage levels increase with the 
adult burden of infection. 
Age-intensity profiles shown in Figure 1A were used. 
Recommendations are for a single community (set at 500 individuals in the model). 
Corresponding parameter values, including prevalence threshold values for the age-
intensity profiles investigated, are shown in Supplementary Tables 1–5.
Abbreviations: EPHP, elimination as a public health problem; SAC, school-aged children 
5–14 years old; y, year(s).
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Figure 2. Schematic of nonlinear relationship between prevalence of infection 
and heavy-intensity infections prior to treatment for low (blue) and high (red) worm 
aggregation populations. Dashed line, prevalence of heavy-intensity infections is 
1%, that is elimination as a public health problem (EPHP) is achieved for school-
aged children 5–14 years old settings falling below this threshold.
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1%), the prevalence of infection may still be high. This is due to 
light- to moderate-intensity infections persisting in SAC, in ad-
dition to light- to heavy-intensity infections remaining in pre-
SAC and adults [13]. Hence, achieving EPHP may not equate 
to low levels of morbidity in non-SAC age groups and, further-
more, stopping treatment after achieving EPHP will likely lead 
to resurgence [16].
Alternative morbidity metrics have been proposed, such as 
prevalence of chronic and/or anatomic findings and quantifi-
able functional morbidities among SAC [17]. Further work is 
also needed for determining whether heavy-intensity infections 
in SAC is an informative indicator of adult morbidity. It is also 
important to consider the varying sensitivity of different diag-
nostic techniques when defining the goal. For example, due to 
its low sensitivity at low prevalence levels, a Kato-Katz preva-
lence measure is likely to be lower than a point-of-care circu-
lating cathodic antigen prevalence measure [18–21].
DISCUSSION
School-Based Versus Community-Wide Treatment
The epidemiological setting influences whether school-based (SAC 
only) or community-wide (SAC and adult) treatment should be im-
plemented. To prevent unnecessary treatment, targeting SAC only 
in low- to moderate-prevalence settings is sufficient for achieving 
EPHP. Community-wide treatment is not necessary in all high-
prevalence settings. However, once a specific prevalence threshold 
is exceeded (determined by the epidemiological setting; Table 1), 
community-wide treatment becomes necessary. This threshold in-
creases as the burden of infection in adults decreases (Figure 1B). As 
S. haematobium tends to have a low burden in adults, the threshold 
to necessitate community-wide MDA for this species is high (sim-
ilar to S. mansoni with a low adult burden setting).
Due to the age profile of infection playing a key role in de-
termining the optimal treatment strategy, it is vital that data are 
collected on the intensity of infection in each age group, specifi-
cally from SAC and adults in high-prevalence settings [12]. The 
data collected need to be representative of the age group, for ex-
ample, sampling from only high-risk adults would overestimate 
the benefit of community-wide treatment [14]. Decisions of 
whether school or community-wide treatment are appropriate 
also need to consider the levels of school enrolment and treat-
ment adherence within the area. With low levels of enrolment 
and SAC adherence, community-wide strategies may be more 
beneficial [14].
Future Steps
As we move towards the 2030 WHO goals and treatment guide-
lines for schistosomiasis, it is vital that the optimal treatment 
strategies are recommended. This includes consideration of the 
epidemiological setting to determine whether school-based or 
community-wide treatment strategies are required for achieving 
EPHP. Community-wide treatment should be prioritized in set-
tings where baseline prevalence is high (more specifically above 
a certain threshold determined by the age profile of infection) 
and where there is low school enrolment [12–14]. Ideally, rather 
than generalizing the treatment strategy by simply categorizing 
into low, moderate, and high baseline prevalence settings, treat-
ment strategies should be determined based on key epidemio-
logical factors in a given setting.
To prevent resurgence after achieving EPHP, programs will 
need to reassess their treatment strategies to either maintain 
EPHP or move towards interruption of transmission. With in-
terruption as the goal, community-wide treatment is likely to 
be essential, alongside interventions such as improved water, 
sanitation, and hygiene (WASH) with behavior change [14, 22]. 
Currently, the ongoing Geshiyaro study is aiming to determine 
whether it is possible to achieve elimination with MDA alone in 
a region of Ethiopia with low S. mansoni prevalence.
As the epidemiological setting plays a key role in determining 
the optimal treatment strategy, mapping of areas is important. 
Development of mapping protocols (which capture key epide-
miological parameters) will allow for more informed decisions 
to be made, thereby reducing overtreatment and allowing for 
treatment to be targeted to areas where it is needed. For ex-
ample, sampling fewer SAC in more schools rather than many 
SAC in few schools has been found to increase the accuracy of 
prevalence estimates [23].
Universal health coverage, ensuring all those in need of treat-
ment have equitable access to it, is a key objective for WHO. In 
addition to MDA, integration of treatment within local health 
systems would help ensure that treatment is available when 
needed [24]. More adult praziquantel donations are also needed. 
Furthermore, complementary interventions, such as WASH, be-
havior change, snail control, and a schistosome vaccine, could 
aid in the achievement of EPHP and interruption of transmis-
sion [25, 26]. Development of a pediatric formulation of pra-
ziquantel may also reduce transmission sooner, particularly in 
settings where pre-SAC harbor a high burden of infection.
In summary, to achieve EPHP, community-wide treatment 
needs to be prioritized in certain high-transmission settings 
(determined by the epidemiological setting, ie, factors such as 
the species present, prevalence prior to treatment, and age pro-
file of infection) as well as settings with low school enrolment. 
However, in low- to moderate-transmission settings with good 
levels of school enrolment, school-based treatment is sufficient 
for achieving EPHP. By highlighting these insights, we hope 
to inform discussions on the schistosomiasis WHO treatment 
guidelines within the new roadmap for NTDs.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
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Notes
Acknowledgments. We thank James E.  Truscott for devel-
oping an initial version of the Imperial College London model 
code. We also thank the Global Schistosomiasis Alliance for 
facilitating important schistosomiasis meetings.
Financial support. This work was supported by the Bill and 
Melinda Gates Foundation (grant number OPP1184344 to the 
Neglected Tropical Diseases Modelling Consortium, J. T., C. H. 
K., G. F. M., D. H., and R. M. A.); and the Wellcome Trust (grant 
number 089276/B/09/7 to H. C. T.).
Potential conflicts of interest. All authors: No reported con-
flicts of interest. All authors have submitted the ICMJE Form 
for Disclosure of Potential Conflicts of Interest. Conflicts that 
the editors consider relevant to the content of the manuscript 
have been disclosed.
References
1. World Health Organization. Update on the global status of 
implementation of preventive chemotherapy (PC), 2019. 
https://www.who.int/neglected_diseases/preventive_che-
motherapy/PC_Update.pdf. Accessed 25 November 2019.
2. World Health Organization. Schistosomiasis: progress re-
port 2001–2011 and strategic plan 2012–2020, 2013. https://
www.who.int/schistosomiasis/resources/9789241503174/
en/. Accessed 25 November 2019. 
3. World Health Organization. Accelerating work to over-
come the global impact of neglected tropical diseases, 
2012. https://www.who.int/neglected_diseases/NTD_
RoadMap_2012_Fullversion.pdf. Accessed 25 November 
2019.
4. WHO Expert Committee. Prevention and control of schis-
tosomiasis and soil-transmitted helminthiasis. World Health 
Organ Tech Rep Ser 2002; 912:i–vi, 1–57, back cover.
5. World Health Organization. Helminth control in school-
age children: A  guide for managers of control pro-
grammes, 2011. https://www.who.int/neglected_diseases/
resources/9789241548267/en/. Accessed 25 November 2019.
6. World Health Organization. Preventive chemotherapy in 
human helminthiasis: coordinated use of anthelminthic 
drugs in control interventions: a manual for health profes-
sionals and programme managers, 2006. https://apps.who.
int/iris/bitstream/handle/10665/43545/9241547103_eng.
pdf?sequence=1. Accessed 25 November 2019.
7. Reinhard-Rupp J, Klohe K. Developing a comprehensive re-
sponse for treatment of children under 6 years of age with 
schistosomiasis: research and development of a pediatric 
formulation of praziquantel. Infect Dis Poverty 2017; 6:122.
8. N’Goran  E, David  Aka  NA, Ouattara  M, Huber  E, 
Bezuidenhout D, Kourany-Lefoll E; Pediatric Praziquantel 
Consortium. Challenges and lessons from conducting a 
paediatric clinical trial in sub-Saharan Africa: the case of 
the praziquantel oral dispersible tablets phase II study in 
Côte d’Ivoire. Adv Parasitol 2019; 103:75–89.
9. World Health Organization. New agreement expands 
access to schistosomiasis treatment for millions, 2013. 
https://www.who.int/neglected_diseases/schistosomiasis_
Merck_2013/en/. Accessed 25 November 2019.
10. World Health Organization. WHO extends deadline of 
second-phase web consultation for new Roadmap on 
neglected tropical diseases. https://www.who.int/ne-
glected_diseases/news/WHO-global-consultations-for-
new-Roadmap-on-NTD/en/. Accessed 25 November 
2019.
11. Anderson RM, Turner HC, Farrell SH, Truscott JE. Studies 
of the transmission dynamics, mathematical model devel-
opment and the control of schistosome parasites by mass 
drug administration in human communities. Adv Parasitol 
2016; 94:199–246.
12. Toor J, Turner HC, Truscott  JE, et al. The design of schis-
tosomiasis monitoring and evaluation programmes: the 
importance of collecting adult data to inform treatment 
strategies for Schistosoma mansoni. PLoS Negl Trop Dis 
2018; 12:e0006717.
13. Toor J, Alsallaq R, Truscott JE, et al. Are we on our way to 
achieving the 2020 goals for schistosomiasis morbidity con-
trol using current world health organization guidelines? 
Clin Infect Dis 2018; 66:S245–52.
14. Turner HC, Truscott JE, Bettis AA, et al. Evaluating the var-
iation in the projected benefit of community-wide mass 
treatment for schistosomiasis: implications for future eco-
nomic evaluations. Parasit Vectors 2017; 10:213.
15. Truscott JE, Gurarie D, Alsallaq R, et al. A comparison of 
two mathematical models of the impact of mass drug ad-
ministration on the transmission and control of schistoso-
miasis. Epidemics 2017; 18:29–37.
16. NTD Modelling Consortium Schistosomiasis Group. 
Insights from quantitative and mathematical modelling on 
the proposed WHO 2030 goal for schistosomiasis. Gates 
Open Res 2019; 3:1517.
17. French MD, Evans D, Fleming FM, et al. Schistosomiasis 
in Africa: improving strategies for long-term and sus-
tainable morbidity control. PLoS Negl Trop Dis 2018; 
12:e0006484.
18. Prada  JM, Touloupou  P, Adriko  M, Tukahebwa  EM, 
Lamberton PHL, Hollingsworth TD. Understanding the re-
lationship between egg- and antigen-based diagnostics of 
Schistosoma mansoni infection pre- and post-treatment in 
Uganda. Parasit Vectors 2018; 11:21.
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/advance-article-abstract/doi/10.1093/infdis/jiz609/5673803 by London School of H
ygiene & Tropical M
edicine user on 07 January 2020
S6 • jid 2019:XX (XX XXXX) • Toor et al
19. Bärenbold O, Garba A, Colley DG, et al. Translating preven-
tive chemotherapy prevalence thresholds for Schistosoma 
mansoni from the Kato-Katz technique into the point-of-
care circulating cathodic antigen diagnostic test. PLoS Negl 
Trop Dis 2018; 12:e0006941.
20. Lamberton PH, Kabatereine NB, Oguttu DW, Fenwick A, 
Webster  JP. Sensitivity and specificity of multiple Kato-
Katz thick smears and a circulating cathodic antigen test 
for Schistosoma mansoni diagnosis pre- and post-repeated-
praziquantel treatment. PLoS Negl Trop Dis 2014; 8:e3139.
21. Viana  AG, Gazzinelli-Guimarães  PH, Castro  VN, et  al. 
Discrepancy between batches and impact on the sensitivity of 
point-of-care circulating cathodic antigen tests for Schistosoma 
mansoni infection. Acta Trop 2019; 197:105049.
22. Knopp S, Person B, Ame SM, et al. Evaluation of integrated 
interventions layered on mass drug administration for 
urogenital schistosomiasis elimination: a cluster-randomised 
trial. Lancet Glob Health 2019; 7:e1118–29.
23. Knowles SCL, Sturrock HJW, Turner H, et al. Optimising 
cluster survey design for planning schistosomiasis preven-
tive chemotherapy. PLoS Negl Trop Dis 2017; 11:e0005599.
24. Chami GF, Bundy DAP. More medicines alone cannot en-
sure the treatment of neglected tropical diseases. Lancet 
Infect Dis 2019; 19:e330–6.
25. Kura K, Truscott JE, Toor J, Anderson RM. Modelling the 
impact of a Schistosoma mansoni vaccine and mass drug ad-
ministration to achieve morbidity control and transmission 
elimination. PLoS Negl Trop Dis 2019; 13:e0007349.
26. Vaz Nery S, Pickering AJ, Abate E, et al. The role of water, 
sanitation and hygiene interventions in reducing soil-
transmitted helminths: interpreting the evidence and 
identifying next steps. Parasit Vectors 2019; 12:273.
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/advance-article-abstract/doi/10.1093/infdis/jiz609/5673803 by London School of H
ygiene & Tropical M
edicine user on 07 January 2020
